Clinical trialsCompany release

MetaVia details DA-1726 interim data and vanoglipel MASH plans in investor deck

🇺🇸 MetaVia Inc. (MTVA) · Fri 13 Nov 2026

The US biotech reports early DA-1726 liver-fat and weight data from a very small cohort, and sets out FDA, Phase 2a and Phase 2 steps, with $8.8M in cash.

MetaVia has set out its liver-focused cardiometabolic pipeline in a corporate presentation dated November 2026. The deck reports interim Part 3B data for DA-1726 and Phase 2a results for vanoglipel in MASH (metabolic dysfunction-associated steatohepatitis). Its title refers to five catalysts through early 2027.

For DA-1726, the company reports liver fat reduction of about 68% and placebo-adjusted weight loss of 13.5%. The summary of the presentation stresses that these figures come from a very small cohort, so they should be read as early signals rather than firm efficacy estimates.

On vanoglipel, MetaVia plans an FDA meeting in the second half of 2026 on a combination with resmetirom. It then plans to start a combination Phase 2a study in the first half of 2027. For DA-1726, a Phase 2 study in MetALD/ALD (metabolic dysfunction and alcohol-related liver disease, and alcohol-related liver disease) is planned for the second half of 2027.

The company reported cash of $8.8M as of 30 September 2026. The material available does not say how long that funding is expected to last or how the planned trials will be financed.

What it means for your team

  • The FDA meeting on vanoglipel plus resmetirom is the next regulatory milestone. Its outcome will shape the design and timing of the planned combination Phase 2a study.
  • The DA-1726 figures are interim and come from a very small cohort. Treat them as preliminary until larger datasets are available.
  • Planned work in MetALD/ALD would extend the programme into a different liver-disease population, with a Phase 2 start targeted for 2H 2027.
  • With $8.8M in cash at 30 September 2026, the funding position is relevant to anyone assessing the pace of development or partnering prospects.

Company's press release (SEC filing): MetaVia Inc. ↗

Article written by VigiEye from the official source (MetaVia Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →